Cargando…
Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases
Liver diseases represent a major global health issue, and currently, liver transplantation is the only viable alternative to reduce mortality rates in patients with end-stage liver diseases. However, scarcity of donor organs and risk of recidivism requiring a re-transplantation remain major obstacle...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072646/ https://www.ncbi.nlm.nih.gov/pubmed/32046114 http://dx.doi.org/10.3390/cells9020386 |
_version_ | 1783506454983999488 |
---|---|
author | Cernigliaro, Viviana Peluso, Rossella Zedda, Beatrice Silengo, Lorenzo Tolosano, Emanuela Pellicano, Rinaldo Altruda, Fiorella Fagoonee, Sharmila |
author_facet | Cernigliaro, Viviana Peluso, Rossella Zedda, Beatrice Silengo, Lorenzo Tolosano, Emanuela Pellicano, Rinaldo Altruda, Fiorella Fagoonee, Sharmila |
author_sort | Cernigliaro, Viviana |
collection | PubMed |
description | Liver diseases represent a major global health issue, and currently, liver transplantation is the only viable alternative to reduce mortality rates in patients with end-stage liver diseases. However, scarcity of donor organs and risk of recidivism requiring a re-transplantation remain major obstacles. Hence, much hope has turned towards cell-based therapy. Hepatocyte-like cells obtained from embryonic stem cells or adult stem cells bearing multipotent or pluripotent characteristics, as well as cell-based systems, such as organoids, bio-artificial liver devices, bioscaffolds and organ printing are indeed promising. New approaches based on extracellular vesicles are also being investigated as cell substitutes. Extracellular vesicles, through the transfer of bioactive molecules, can modulate liver regeneration and restore hepatic function. This review provides an update on the current state-of-art cell-based and cell-free strategies as alternatives to liver transplantation for patients with end-stage liver diseases. |
format | Online Article Text |
id | pubmed-7072646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70726462020-03-19 Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases Cernigliaro, Viviana Peluso, Rossella Zedda, Beatrice Silengo, Lorenzo Tolosano, Emanuela Pellicano, Rinaldo Altruda, Fiorella Fagoonee, Sharmila Cells Review Liver diseases represent a major global health issue, and currently, liver transplantation is the only viable alternative to reduce mortality rates in patients with end-stage liver diseases. However, scarcity of donor organs and risk of recidivism requiring a re-transplantation remain major obstacles. Hence, much hope has turned towards cell-based therapy. Hepatocyte-like cells obtained from embryonic stem cells or adult stem cells bearing multipotent or pluripotent characteristics, as well as cell-based systems, such as organoids, bio-artificial liver devices, bioscaffolds and organ printing are indeed promising. New approaches based on extracellular vesicles are also being investigated as cell substitutes. Extracellular vesicles, through the transfer of bioactive molecules, can modulate liver regeneration and restore hepatic function. This review provides an update on the current state-of-art cell-based and cell-free strategies as alternatives to liver transplantation for patients with end-stage liver diseases. MDPI 2020-02-07 /pmc/articles/PMC7072646/ /pubmed/32046114 http://dx.doi.org/10.3390/cells9020386 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Cernigliaro, Viviana Peluso, Rossella Zedda, Beatrice Silengo, Lorenzo Tolosano, Emanuela Pellicano, Rinaldo Altruda, Fiorella Fagoonee, Sharmila Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases |
title | Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases |
title_full | Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases |
title_fullStr | Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases |
title_full_unstemmed | Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases |
title_short | Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases |
title_sort | evolving cell-based and cell-free clinical strategies for treating severe human liver diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072646/ https://www.ncbi.nlm.nih.gov/pubmed/32046114 http://dx.doi.org/10.3390/cells9020386 |
work_keys_str_mv | AT cernigliaroviviana evolvingcellbasedandcellfreeclinicalstrategiesfortreatingseverehumanliverdiseases AT pelusorossella evolvingcellbasedandcellfreeclinicalstrategiesfortreatingseverehumanliverdiseases AT zeddabeatrice evolvingcellbasedandcellfreeclinicalstrategiesfortreatingseverehumanliverdiseases AT silengolorenzo evolvingcellbasedandcellfreeclinicalstrategiesfortreatingseverehumanliverdiseases AT tolosanoemanuela evolvingcellbasedandcellfreeclinicalstrategiesfortreatingseverehumanliverdiseases AT pellicanorinaldo evolvingcellbasedandcellfreeclinicalstrategiesfortreatingseverehumanliverdiseases AT altrudafiorella evolvingcellbasedandcellfreeclinicalstrategiesfortreatingseverehumanliverdiseases AT fagooneesharmila evolvingcellbasedandcellfreeclinicalstrategiesfortreatingseverehumanliverdiseases |